Ari Zimran

Novel oral treatment of Gaucher's disease with N-butyldeoxynojirimycin (OGT 918) to decrease substrate biosynthesis

Timothy M. Cox, Robin Lachmann, C. E. Hollak et al. · The Lancet · 2000 · 744 citations

Medicine, Pharmacology, Pharmacotherapy +4

The Gaucher Registry

Joel Charrow, Hans C. Andersson, Paige Kaplan et al. · Archives of Internal Medicine · 2000 · 585 citations

Life Sciences, Genetics, Molecular Genetics +17

Occurrence of Parkinson's syndrome in type 1 Gaucher disease

Orit Neudorfer, Nir Giladi, Deborah Elstein et al. · QJM · 1996 · 396 citations · Full text

Medicine, Neurology, Neuroscience +17

Sustained therapeutic effects of oral miglustat (Zavesca, <i>N</i>‐butyldeoxynojirimycin, OGT 918) in type I Gaucher disease

Deborah Elstein, Carla E. M. Hollak, Johannes M. F. G. Aerts et al. · Journal of Inherited Metabolic Disease · 2004 · 233 citations

Pharmacy, Pharmacotherapy, Neurobiology Of Disease +3

Gaucher disease and cancer incidence: a study from the Gaucher Registry

Barry E. Rosenbloom, Neal J. Weinreb, Ari Zimran et al. · Blood · 2005 · 231 citations

Medicine, Health Sciences, Oncology +16